Patent For Therapeutic Skin Treatment Awarded to Topix Pharmaceuticals

Formulation contains sodium hyaluronate, an oligopeptide, antioxidants, Camellia sinensis leaf extract, resveratrol, ectoin and more.

US Patent No. 11,433,006 B2 (Steven M. Hernandez); Topix Pharmaceuticals, Inc., North Amityville, NY, has been awarded a patent for a topical therapeutic treatment for skin in dermatological procedures. It is comprised of sodium hyaluronate; an oligopeptide (wherein the oligopeptide is 0.0001%-10% palmitoyl sh-tripeptide-4 amide on an active basis); one or more antioxidants (wherein the one or more antioxidants is between 0.1%-10% w/w and comprises one or more of Camellia sinensis leaf extract, resveratrol, ectoin, Cucumis satvius fruit extract, ergothioneine, Phyllanthus emblica fruit extract); purified water; hydrolyzed sodium hyaluronate; Camellia sinensis leaf extract; resveratrol; ectoin; ergothioneine; bisabolol; Cucumis satvius fruit extract; sodium pyrrolidone carboxylic acid (PCA); Chamomila recutita flower extract; comfrey extract; yucca glauca root extract; Phyllanthus emblica fruit extract; caffeine; sodium phosphate; potassium hydroxide; phenylcarbinol; sodium benzoate; disodium Ethylenediaminetetraacetic acid (EDTA); and polysorbate 20.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters